Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kinetoplast DNA (kDNA) is a large, complex, disk-shaped network of circular double-stranded DNA molecules localized within the single mitochondrion of trypanosomatid protozoa such as Trypanosoma brucei and Trypanosoma cruzi. The network consists of thousands of interlinked minicircles (0.5–10 kb) and dozens of larger maxicircles (20–40 kb). The maxicircles encode components of the mitochondrial transcriptome (such as rRNAs and subunits of respiratory complexes), and the minicircles mainly encode guide RNAs required for the extensive RNA editing of maxicircle transcripts[1][5][7]. The kDNA is physically connected by the tripartite attachment complex (TAC) to the basal bodies of the flagellum, ensuring faithful segregation during cell division[5][6][7]. Maintenance and replication of this DNA is essential for parasite survival, making enzymes involved in kDNA metabolism (such as topoisomerases, DNA polymerases, and helicases) potential drug targets, but kDNA itself, as a DNA network, is not a 'target' in the conventional sense[2][5][7]. Important note: Kinetoplast DNA is *not* a conventional therapeutic target like a receptor, enzyme, or transporter. Rather, several *enzymes and proteins* involved in its replication, repair, and maintenance—such as DNA polymerase β, helicases (PIF1-like), and others—are considered potential drug targets in anti-trypanosomatid therapy[2][5]. Some drugs, such as certain DNA intercalators or topoisomerase inhibitors, can disrupt kDNA, but they do so through indirect actions on these enzymes or by interfering with DNA structure.
Null (not applicable, as kDNA is not the direct molecular target of drugs; some compounds disrupt kDNA replication or maintenance indirectly)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kinetoplast DNA of trypanosome (kDNA).